MedTrace Logo

Genistein, Equol, Cognitive Function and Mood: Acute. (GECFAMa)

NCT07742514 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2026-08-07

No results posted yet for this study

Summary

Isoflavones (ISF) are naturally occurring compounds that can provide protective benefits for certain domains of cognitive function. Studies on the prevalence of cognitive decline and cancers in the Asian diet-eating areas of the world have investigated the effects of the ISFs and how they affect our bodies and brains. Previous literature has shown that ISFs are capable of binding oestrogen receptors in our brains that provide protection in terms of antioxidation, anti-inflammatory and promoting the growth and interaction of our brain cells.

Genistein is an important ISF having been shown to provide a strong protective response in our brains and other aspects of healthcare; Equol is a metabolite of ISF and is thought to provide a similar (or stronger) response than Genistein due to its receptor binding strength. Unfortunately, not everyone is capable of digesting Equol from other Isoflavones (Daidzein) and therefore supplementing this directly could provide neurological benefits at a similar level, if not stronger than, Genistein.

This acute study will aim to evaluate the efficacies of two ISFs (Genistein and Equol) versus a control group, in an immediately post-prandial timeframe. SIF are "Generally Recognised As Safe" ("GRAS") molecules by the United States of America's classification regulatory commission the Federal Drug Administration as well as deemed "Safe" by the European Food Safety Authority (EFSA). Participant will be required to undertake 2 one hour-long sessions. Interventions will be taken once after the baseline task battery is completed.

Conditions

  • Cognition
  • Mood

Interventions

DIETARY_SUPPLEMENT

Genistein

Genistein is a neuroprotective Isoflavone commonly found in Glycine Max (Soy).

DIETARY_SUPPLEMENT

Equol

Equol is a metabolite of the Isoflavone Daidzein, metabolised in roughly 10-20% of the western population.

DIETARY_SUPPLEMENT

Maltodextrin (Placebo)

Maltodextrin is the placebo control used in this study. A non-neuroactive starch derived polysaccharide .

Sponsors & Collaborators

  • University of Reading

    lead OTHER

Principal Investigators

  • Claire Williams, PhD · University of Reading

  • Daniel Lamport, PhD · University of Reading

  • Luke R Till, MSc · University of Reading

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-11-14
Primary Completion
2025-10-14
Completion
2025-10-14

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07742514 on ClinicalTrials.gov